Instruction 1(b)

1. T

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

pursuant to Section 16(a) of the Securities Exchange Act of 1934	
pursuant to be blon 10(a) of the becantics Exchange 7 of of 1004	
or Section 30(h) of the Investment Company Act of 1940	

			or Section 30(h) of the Investment Company Act of 1940						
1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol <u>Ultragenyx Pharmaceutical Inc.</u> [ RARE ]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Aliski William				X	Director	10% Owner			
(Last) C/O ULTRAC 60 LEVERON		(Middle) MACEUTICAL INC.	3. Date of Earliest Transaction (Month/Day/Year) 02/05/2014		Officer (give title below)	Other (specify below)			
(Street) NOVATO CA 94949		94949	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv X	Form filed by One Rep	g (Check Applicable Line porting Person an One Reporting Person			
(City)	(State)	(Zip)							
		Table I - Non-De	rivative Securities Acquired, Disposed of, or Ben	eficially O	wned				

Title of Security (Instr. 3)	Date (Month/Day/Year)		nstr.		D) (Instr. 3	, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	(D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
		Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Socurity	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		(A) or Dis			Expiration Date of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
	Security			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	(I) (Instr. 4)	
Warrant to Purchase Series A Preferred Stock (Right to Buy)	\$0.959	02/05/2014		J			91,241 <sup>(1)</sup>	06/16/2011	02/23/2021	Series A Preferred Stock	91,241	\$0.00	0	D	
Warrant to Purchase Common Stock (Right to Buy)	\$3.01	02/05/2014		J		29,108 <sup>(1)</sup>		06/16/2011	02/23/2021	Common Stock	29,108	\$0.00	0	D	

Explanation of Responses:

1. Immediately prior to the closing of the Issuer's initial public offering, this warrant to purchase shares of Series A Preferred Stock automatically converted on a 1-for-3.1345 basis into a warrant to purchase shares of Common Stock. Disposition of Warrant to Purchase Series A Preferred Stock and acquisition of Warrant to Purchase Common Stock listed solely for the purpose of reporting such conversion of the shares underlying the security.

## **Remarks**:

By: /s/ Ryan Murr by power of

02/06/2014

\*\* Signature of Reporting Person

attorney for William Aliski

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Date